GLSI

Greenwich LifeSciences, Inc. (GLSI) | Rumor.io

Greenwich LifeSciences

GLSI

Attention (50-day avg)0%

Attention rank (50-day avg)#1,061

Bullish sentiment (50-day avg)83%

Price to earnings ratio-12.9

Market capitalization272.9M

Earnings per share-1.59

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-19.4M

Social

What share of all stock conversation is about GLSI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Sep 22

Greenwich LifeSciences, Inc. (GLSI) has seen strong management and a good product, with CEO/CFO Snehal Patel continuing to buy shares despite market fluctuations.
CEO Snehal Patel's buying behavior, with dozens of purchases and zero sales, is notable, and he now owns over 5.6 million shares of the company.
GLSI has potential for a 50% move in the coming months, possibly due to a data release, and the stock's low float and momentum algos rotating into SABCS names could contribute to this move.

Generated by AI

Sentiment

Of the messages about GLSI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	93.33% +2.05	87.61% +5.76	79.66% -2.74
Bearish	—	6.67% -2.05	12.39% -5.76	20.34% +2.74

Bullish· Jul 21

The company's low float and high potential make it an attractive investment opportunity, with some analysts expecting a 10x-20x increase in the stock price.
The recent news of the company agreeing to a more rigorous and FDA-friendly trial protocol has improved the stock's prospects, and the CEO's decision to mature the drug and seek a more lucrative deal is seen as a positive step.
The company's CEO, Snehal Patel, has a significant stake in the company and stands to become a post-tax billionaire if the stock price reaches around $240-255 per share, making a $3.5-4 billion buyout plausible.

Bearish· Jul 20

The trial for Greenwich LifeSciences' vaccine may be longer than expected, potentially increasing the length of the trial and changing the design midway through, which may not be favorable to the FDA.
The company may need to extend the lock-up period if the trial is not completed by September, which could lead to a sell-off in the stock.
The trial's potential delay and the changing design may be a major contributor to the stock's 50% drop in the past six months, with institutions suspecting the development and stopping buying the stock.

Generated by AI

Topics

Of the messages about GLSI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	30.95%	45.52%
Technical Analysis	—	100%	47.62%	35.63%
Analysts	—	0%	16.67%	9.29%
Controversies	—	0%	4.76%	0.27%
Earnings	—	0%	0%	0.6%
Macro	—	0%	0%	8.69%

Announcements· Mar 17

Greenwich LifeSciences, Inc. ($GLSI) reported preliminary Phase III FLAMINGO-01 trial data showing a recurrence rate of
The
The FDA has approved the first commercial lot of GP2 vials for use in the FLAMINGO-01 study in the U.S.

Technical Analysis· Jan 22

$GLSI has gapped up and is moving higher, with a possible new base forming at $28-32.
The stock has finally stabilized, with a potential upside target of $28 if the vwap is broken.
A technical analysis of the charts suggests that $GLSI needs to break above $26 to unlock bullish signals, with a potential target of $50-80 if the stock can overcome resistance.

Generated by AI

Community

Of the messages about GLSI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	87.83%	67.98%
Newcomers	0%	0%	12.17%	32.02%

Regulars· Sep 18

The regulars are expecting a potential pump to $18, but are now facing resistance around that price, with some speculating about the possibility of a rejection.
The asset has shown strong volume and good price action, with some participants attributing this to a potentially good week and upcoming positive news.
The regulars are anticipating a test of $20, with some speculating about the possibility of a continuation of the upward trend, but also acknowledging the presence of short sellers.

Newcomers· Jul 21

The newcomer investors are excited about the potential for $GLSI to catapult to a $10B market cap, with some already accumulating shares in anticipation of enormous gains.
The Phase 3 trial progress and expanded study design announced by $GLSI are seen as significant developments, with one investor aiming to buy 1000 more shares to capitalize on the catalyst day.
With a low float and hype surrounding $GLSI, some investors are taking a position around $8, while others are setting ambitious goals, such as accumulating 1000 shares to achieve a life-changing profit.

Generated by AI

News

3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets

Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest.

14d agoYahoo Finance

Why is Greenwich LifeSciences stock rallying today?

1mo agoInvesting.com

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

STAFFORD, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to January 31, 2027 which

1mo agoYahoo Finance

Also Discussed

Investors talking about GLSI also mention

#	Name	Attention
1	BriaCell Therapeutics Corp.BCTX	0%+0
2	SELLAS Life Sciences Group, Inc.SLS	0.56%-0.06
3	Immutep Ltd. ADRIMMP	0.01%-0.02
4	Context Therapeutics Inc.CNTX	0%0
5	Annovis Bio, Inc.ANVS	0%0
6	Oriental Culture Holding Ltd.OCG	0%0
7	Celcuity Inc.CELC	0%0
8	Immunocore Holdings plc ADRIMCR	0%0
9	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
10	Viatris Inc.VTRS	0%0

Greenwich LifeSciences, Inc.

Healthcare
Biotechnology

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its primary program centers on GP2, an investigational peptide-based immunotherapy designed to help prevent breast cancer recurrence after surgery. The company’s research and clinical activities are concentrated on advancing cancer vaccines and immune-based treatments that target HER2-related disease, a major area in oncology where precision therapies play an important role. Greenwich LifeSciences operates as a biotechnology developer rather than a commercial drug producer, with its current work centered on clinical evaluation, safety, and efficacy of its lead candidates. Based in Stafford, Texas, Greenwich LifeSciences is positioned within the broader life sciences sector as a specialized company addressing unmet needs in post-treatment breast cancer care.

Website

Location

Building 14

Stafford, TX, 77477

United States

Social

What share of all stock conversation is about GLSI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Sep 22

Greenwich LifeSciences, Inc. (GLSI) has seen strong management and a good product, with CEO/CFO Snehal Patel continuing to buy shares despite market fluctuations.
CEO Snehal Patel's buying behavior, with dozens of purchases and zero sales, is notable, and he now owns over 5.6 million shares of the company.
GLSI has potential for a 50% move in the coming months, possibly due to a data release, and the stock's low float and momentum algos rotating into SABCS names could contribute to this move.

Generated by AI

Sentiment

Of the messages about GLSI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	93.33% +2.05	87.61% +5.76	79.66% -2.74
Bearish	—	6.67% -2.05	12.39% -5.76	20.34% +2.74

Bullish· Jul 21

The company's low float and high potential make it an attractive investment opportunity, with some analysts expecting a 10x-20x increase in the stock price.
The recent news of the company agreeing to a more rigorous and FDA-friendly trial protocol has improved the stock's prospects, and the CEO's decision to mature the drug and seek a more lucrative deal is seen as a positive step.
The company's CEO, Snehal Patel, has a significant stake in the company and stands to become a post-tax billionaire if the stock price reaches around $240-255 per share, making a $3.5-4 billion buyout plausible.

Bearish· Jul 20

The trial for Greenwich LifeSciences' vaccine may be longer than expected, potentially increasing the length of the trial and changing the design midway through, which may not be favorable to the FDA.
The company may need to extend the lock-up period if the trial is not completed by September, which could lead to a sell-off in the stock.
The trial's potential delay and the changing design may be a major contributor to the stock's 50% drop in the past six months, with institutions suspecting the development and stopping buying the stock.

Generated by AI

Topics

Of the messages about GLSI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	30.95%	45.52%
Technical Analysis	—	100%	47.62%	35.63%
Analysts	—	0%	16.67%	9.29%
Controversies	—	0%	4.76%	0.27%
Earnings	—	0%	0%	0.6%
Macro	—	0%	0%	8.69%

Announcements· Mar 17

Greenwich LifeSciences, Inc. ($GLSI) reported preliminary Phase III FLAMINGO-01 trial data showing a recurrence rate of
The
The FDA has approved the first commercial lot of GP2 vials for use in the FLAMINGO-01 study in the U.S.

Technical Analysis· Jan 22

$GLSI has gapped up and is moving higher, with a possible new base forming at $28-32.
The stock has finally stabilized, with a potential upside target of $28 if the vwap is broken.
A technical analysis of the charts suggests that $GLSI needs to break above $26 to unlock bullish signals, with a potential target of $50-80 if the stock can overcome resistance.

Generated by AI

Community

Of the messages about GLSI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	87.83%	67.98%
Newcomers	0%	0%	12.17%	32.02%

Regulars· Sep 18

The regulars are expecting a potential pump to $18, but are now facing resistance around that price, with some speculating about the possibility of a rejection.
The asset has shown strong volume and good price action, with some participants attributing this to a potentially good week and upcoming positive news.
The regulars are anticipating a test of $20, with some speculating about the possibility of a continuation of the upward trend, but also acknowledging the presence of short sellers.

Newcomers· Jul 21

The newcomer investors are excited about the potential for $GLSI to catapult to a $10B market cap, with some already accumulating shares in anticipation of enormous gains.
The Phase 3 trial progress and expanded study design announced by $GLSI are seen as significant developments, with one investor aiming to buy 1000 more shares to capitalize on the catalyst day.
With a low float and hype surrounding $GLSI, some investors are taking a position around $8, while others are setting ambitious goals, such as accumulating 1000 shares to achieve a life-changing profit.

Generated by AI

Greenwich LifeSciences

Social

Sep 22

Bullish· Jul 21

Bearish· Jul 20

Announcements· Mar 17

Technical Analysis· Jan 22

Regulars· Sep 18

Newcomers· Jul 21

3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets

Why is Greenwich LifeSciences stock rallying today?

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock

Greenwich LifeSciences CEO Snehal Patel buys $20,430 in shares

Greenwich LifeSciences CEO buys $47,018 in company stock

Also Discussed

Greenwich LifeSciences, Inc.

Company Information

Location

3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets

Why is Greenwich LifeSciences stock rallying today?

Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027

Greenwich LifeSciences CEO Snehal Patel buys $29,555 in stock

Greenwich LifeSciences CEO Snehal Patel buys $20,430 in shares

Greenwich LifeSciences CEO buys $47,018 in company stock

Also Discussed

Social

Sep 22

Bullish· Jul 21

Bearish· Jul 20

Announcements· Mar 17

Technical Analysis· Jan 22

Regulars· Sep 18

Newcomers· Jul 21